应用接头PCR克隆慢病毒介导的转基因小鼠整合位点旁侧序列

目的为鉴定慢病毒介导的转基因小鼠中外源基因的整合位点信息,应用接头PCR克隆整合位点旁侧序列。方法小鼠基因组总DNA酶解后与设计的接头片段连接,根据慢病毒的LTR序列设计巢式PCR引物,克隆转基因小鼠整合位点旁侧序列。结果成功克隆到转基因小鼠整合位点的旁侧序列,经过测序定位于小鼠染色体上。结论作为反向PCR的改进,本方法可用于转基因小鼠整合位点旁侧序列的克隆,为分析整合位点与外源基因表达之间的关系等提供了科学依据。     

外源性人TIMP-1基因在转基因小鼠染色体上的整合及定位

为探讨外源基因人基质金属蛋白酶组织抑制物-1（human tissue inhibitor of metalloproteinase-1, hTIMP-1）基因在转基因小鼠家系染色体上的整合和精确定位,应用Southrn印迹检测外源基因在染色体上整合的位点及拷贝数.结果表明,外源基因是以单拷贝、单位点形式整合;应用荧光原位杂交（fluorescence in situ hybridization, FISH）技术检测F4～F20代转基因小鼠中外源基因的整合.结果证明,该家系转基因小鼠自F4代起是纯合子,外源基因整合在17号染色体E区;反向PCR法（Inverse PCR, IPCR）克隆出约3.8 kb外源基因整合位点处的侧翼序列.分析表明,外源基因整合在17号染色体E1.3区,ALK（anaplastic lymphoma kinase, ALK）基因第23个内含子区域.结果提示,获得的转基因小鼠为纯系,外源基因hTIMP-1已稳定整合在转基因小鼠染色体上,并能遗传给后代.     

利用Gateway技术构建慢病毒载体及其在鸡囊胚细胞中的表达

目的:建立慢病毒载体介导的外源基因在动物中表达的模式。方法:通过PCR扩增出带EGFP基因和特异性结合位点的DNA序列,并应用Gateway技术构建了带EGFP基因的pLenti6/v5-DEST慢病毒载体。利用磷酸钙介导慢病毒4质粒系统在包装细胞中转染,收集并浓缩产生的病毒颗粒,通过感染293FT细胞测定慢病毒滴度。结果:通过PCR扩增后测序分析,表明慢病毒载体构建正确。病毒滴度测定结果为2×107TU/mL。并用慢病毒对鸡囊胚细胞进行感染,获得了较强的表达效果。结论:慢病毒载体系统所产生的病毒颗粒对动物细胞具有较强的感染能力,为慢病毒载体在转基因家禽研究中的应用奠定了基础。     

成骨细胞特异性表达Cre重组酶转基因小鼠的建立

构建了含有骨钙素基因启动子、Cre重组酶基因和人生长激素基因polyA的转基因载体pOC-Cre, 以显微注射的方法将4.6 kb的转基因片段OC-Cre导入小鼠受精卵。16只子代小鼠中经PCR和Southern杂交鉴定, 有2只小鼠携带外源基因, 整合率为12.5%。为了检测OC-Cre在转基因小鼠中表达的组织特异性, 将转基因首建者小鼠与基因组上携带有LoxP位点的条件性Smad4基因敲除小鼠交配, PCR结果显示, 仅在子代纯合型小鼠骨组织基因组中扩增出了Cre介导重组后的片段。将OC-Cre转基因小鼠与ROSA26报告小鼠交配, 利用LacZ染色对双转基因阳性子代小鼠进行检测, 结果显示Cre重组酶在成骨细胞中特异性表达并介导ROSA基因座LoxP位点间的重组。所有这些结果说明：所建立的OC-Cre转基因小鼠在成骨细胞中特异性表达Cre重组酶, 并能在体内介导成骨细胞基因组上LoxP位点间的重组, 是一种理想的研制成骨细胞特异性基因敲除小鼠的工具小鼠。     

慢病毒载体法制备红色荧光蛋白转基因小鼠

目的利用慢病毒介导的转基因方法制备红色荧光蛋白（mRFP）转基因小鼠,并建立转基因小鼠的技术平台。方法将携带mRFP基因的慢病毒注入ICR鼠单细胞受精卵卵周隙以感染受精卵,胚胎移植进假孕母鼠以获得仔代鼠,然后应用小动物活体成像仪、体视荧光显微镜和PCR等鉴定并获得mRFP转基因鼠。结果移植卵周隙注射有慢病毒的胚胎40枚给2只假孕母鼠,共获得仔鼠6只;利用体视荧光显微镜检测mRFP表达,在蛋白水平证实6只F0代中,2只（R3和R4）鼠耳高表达mRFP,其余的弱表达mRFP（R1、R2和R5）或荧光强度（R6）与野生型ICR鼠无明显差别,而DNA水平检测证实,6只F0代中,5只（R1、R2、R3、R4和R5）基因组中整合有外源转基因hUb-mRFP,预示基因型鉴定结果很好验证了体视荧光显微镜鉴定结果。此外,mRFP转基因首建鼠基因组中整合的mRFP基因可稳定遗传和表达。结论建立了慢病毒法快速制备转基因小鼠的技术平台,这为针对不同基因建立相应转基因小鼠以实现恒定或条件性的转基因过表达或RNA干涉（RNAi）,并进而在体内解析相应基因功能和建立人类疾病模型等奠定了坚实基础。     

外源基因在转基因玉米中的整合位点分析

玉米是我国第一大作物,在保障我国粮食安全中发挥重要作用。通过转基因技术培育具有抗病虫等性状的转基因玉米新品种,可有效减少产量损失。培育的转基因玉米需要鉴定外源基因整合位点,为转基因玉米的安全性评价提供重要依据。以一个抗虫转基因玉米事件IE34为材料,采用热不对称PCR(TAIL-PCR)和遗传定位方法,鉴定外源基因整合位点及旁侧序列。通过TAIL-PCR得到一段长度为776 bp的玉米基因组序列。分别在旁侧序列和外源基因上游序列设计特异性引物,建立了转基因玉米事件特异性的PCR鉴定方法。将旁侧序列在MaizeGDB中进行比对分析,发现此序列是重复序列而且存在于多条染色体上。构建转基因玉米IE34与自交系B73的F2代遗传分离群体,通过BSR-Seq方法确定外源基因整合在玉米第5染色体短臂2.32-2.70Mb区间内。通过精细定位将外源基因整合位点缩小在第5染色体2.35-2.61 Mb约260 kb的区间内。本研究结果表明,对于整合位点旁侧序列复杂的转基因事件,TAIL-PCR结合遗传定位方法能够有效鉴定外源基因的整合位点。     

慢病毒介导Nanog基因在小鼠ES细胞的表达

试验尝试构建小鼠Nanog基因慢病毒表达载体,培养表达外源Nanog基因的小鼠ES细胞。结果显示通过RT-PCR扩增出918bp的小鼠Nanog基因,测序正确的小鼠Nanog基因通过慢病毒介导在小鼠ES细胞表达后,表达外源Nanog基因的小鼠ES细胞生长状态同普通ES细胞无明显差异,在无LIF的ES细胞培养液培养条件下,表达外源Nanog基因的小鼠ES细胞保持正常的ES细胞集落,碱性磷酸酶、Oct4和SSEA-1免疫细胞化学检测为阳性,相同情况下未表达外源Nanog基因的小鼠ES细胞集落退化消失。试验证实了通过慢病毒载体介导培养了表达外源Nanog基因的小鼠ES细胞。试验尝试构建小鼠Nanog基因慢病毒表达载体,培养表达外源Nanog基因的小鼠ES细胞。根据小鼠Nanog基因m RNA序列设计Nanog基因引物,引物两端带有Nhe I和Xho I酶切位点。Trizol试剂处理小鼠ES细胞,通过RT-PCR扩增出小鼠Nanog基因,小鼠Nanog基因用Nhe I和Xho I酶切后连入pcDNA3.1载体中,PCR检测阳性的细菌克隆进行测序,测序正确的Nanog基因片段连接入PLL-IRES-Neo慢病毒表达载体中,包装含有Nanog基因的慢病毒感染小鼠ES细胞,在SNL细胞饲养层上G418筛选2周后,添加普通ES细胞培养液在普通小鼠胎儿成纤维细胞饲养层上培养。结果显示通过RT-PCR扩增出918 bp的小鼠Nanog基因,测序正确的小鼠Nanog基因通过慢病毒介导在小鼠ES细胞表达后,表达外源Nanog基因的小鼠ES细胞生长状态同普通ES细胞无明显差异,在无LIF的ES细胞培养液培养条件下,表达外源Nanog基因的小鼠ES细胞保持正常的ES细胞集落,碱性磷酸酶、Oct4和SSEA-1免疫细胞化学检测为阳性,相同情况下未表达外源Nanog基因的小鼠ES细胞集落退化消失。试验证实了通过慢病毒载体介导培养了表达外源Nanog基因的小鼠ES细胞。     

介导大鼠结缔组织生长因子基因沉默的慢病毒载体转移质粒的构建及鉴定

目的：构建介导大鼠结缔组织生长因子（CTGF）基因沉默的慢病毒载体转移质粒pGCL-CTGF,为进一步包装慢病毒载体奠定基础。方法：以大鼠CTGF基因为靶基因,根据RNA干扰（RNAi）序列设计原则,设计4对有小发夹结构的RNAi靶点序列,退火形成双链DNA,双酶切后定向克隆到慢病毒载体转移质粒pGCL-GFP中,构建4个含靶基因片段的重组慢病毒载体转移质粒pGCL-CTGF,并对质粒进行PCR及测序鉴定。结果：CTGF的短发夹RNA（shRNA）片段被成功克隆到慢病毒载体转移质粒pGCL-GFP中,4个插入序列与设计的靶基因片段完全一致。结论：构建了能够表达4个含CTGF靶基因片段的慢病毒载体转移质粒,为进一步包装介导CTGF基因沉默的慢病毒载体奠定了基础。     

外源基因在转基因小鼠中遗传和表达的稳定性

通过显微注射将外源构件λ１０６（年α－Ｓ１酪蛋白基因调控区指导的乙肝病毒表面抗原基因表达构件）导入小鼠受精卵中,用ＰＣＲ－Ｓｏｕｔｈｅｍ方法进行外源基因的整合检测、ＥＬＩＳＡ法进行外源基因的表达检测,对４代转基因小鼠进行了跟踪测定,结果表明：的代转基因小鼠的整合率为５６％,原代雌鼠乳汁中转基因产物的表达率为１００％;传代跟踪基因的整合率不符合“单一位点随机整合”的假说,家系分析推测外源基因在受精卵     

A high throughput method for genome-wide analysis of retroviral integration

Retroviral and lentiviral vectors integrate their DNA into the host cell genome leading to stable transgene expression. Integration preferentially occurs in the proximity of active genes, and may in some case disturb their activity, with adverse toxic consequences. To efficiently analyze high numbers of lentiviral insertion sites in the DNA of transduced cells, we developed an improved high-throughput method called vector integration tag analysis (VITA). VITA is based on the identification of Genomic Tags associated to the insertion sites, which are used as signatures of the integration events. We use the capacity of MmeI to cleave DNA at a defined distance of its recognition site, in order to generate 21 bp long tags from libraries of junction fragments between vector and cellular DNA. The length of the tags is sufficient in most cases, to identify without ambiguity an unique position in the human genome. Concatenation, cloning and sequencing of the tags allow to obtain information about 20–25 insertion sites in a single sequencing reaction. As a validation of this method, we have characterized 1349 different lentiviral vector insertion sites in transduced HeLa cells, from only 487 sequencing reactions, with a background of <2% false positive tags.     

AKT2基因短发夹结构RNA慢病毒载体的构建及鉴定

目的：构建丝/苏氨酸蛋白激酶2（AKT2）基因RNA干扰（RNAi）慢病毒载体。方法：利用公用网站按照RNAi序列设计原则,设计RNAi靶点序列并合成靶序列的Oligo DNA,退火形成双链DNA,与经MluI和ClaI进行酶切后的PLVTHM载体连接产生shRNA慢病毒载体。应用shRNA慢病毒载体转染293T细胞及U87细胞,测定病毒滴度,流式细胞仪测定U87细胞的转染效率,PCR及Western blot鉴定AKT2基因在U87细胞中的下调作用。结果：成功构建了shRNA-AKT2慢病毒载体,经测序与设计合成的靶向链完全一致。荧光显微镜下观察293T细胞感染效率大于90%,病毒滴度为3.59×107TU/ml;流式细胞仪测定对AKT2细胞的转染效率为86.93%。PCR测定shRNA载体感染U87细胞后AKT2的干扰效率为68%。Western Blot结果显示该慢病毒载体对AKT2的表达有较为显著的敲减作用。结论：成功构建了人胶质瘤细胞株AKT2基因RNAi慢病毒载体,为后续的体内外功能学试验创造了条件。     

Modeling heterochromatin regions in transgenic mice

Transgenic mice carrying bovine satellite DNA IV were obtained. The size of the transgene integrated into the mouse genome was approximately 390 kb (about 100 transgene copies) as determined by a semiquantitative PCR. Restriction analysis with isoschizomeric restrictases HpaII and MspI, showed that the alien DNA was methylated. In the genome of a transgenic founder male, two integration sites for satellite DNA IV were revealed by in situ hybridization and in situ PCR. These sites are situated on two different chromosomes: in pericentromeric heterochromatin and within a chromosomal arm. In transgenic mice, de novo formation of heterochromatin regions (C-block and the CMA3 disk within the centromeric heterochromatin of another chromosome) was revealed by C-banding and staining with chromomycin A3. This formation is not characteristic of mice, because their chromosomes normally contain no interstitial C-blocks or sequences intensely stained by chromomycin A3.     

基于XcmⅠ酶切的高效TA克隆载体的构建

目的：制备基于XcmⅠ酶切的高效TA克隆载体,并检测其克隆PCR产物的效果。方法：设计一对互补配对的寡核苷酸,经过变性及退火后插入质粒pUC19的多克隆位点,从而在该多克隆位点中引入2个XcmⅠ酶切位点,用XcmⅠ酶切后即获得含有3’突出T碱基的T载体;为了提高该T载体的克隆效率,优化了2个XcmⅠ酶切位点之间的碱基数目,排除了载体自连产生白色克隆的可能性,使假阳性大大减少;此外,为了便于完全酶切与未完全酶切载体的分离,在2个XcmⅠ之间插入了一段无关DNA片段。结果：改进得到的T载体可以有效克隆PCR产物,其阳性克隆率可达95％。结论：构建了基于XcmⅠ酶切的TA克隆载体,经过改进的T载体具有很高的克隆效率。     

Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site,AAVS1, on human chromosome 19

Herpes simplex virus type 1 (HSV-1)-based amplicon vectors have a large transgene capacity and can efficiently infect many different cell types. One disadvantage of HSV-1 vectors is their instability of transgene expression. By contrast, vectors based on adeno-associated virus (AAV) can either persist in an episomal form or integrate into the host cell genome, thereby supporting long-term gene expression. AAV expresses four rep genes, rep68, -78, -40, and -52. Of those, rep68 or rep78 are sufficient to mediate site-specific integration of the AAV DNA into the host cell genome. The major disadvantage of AAV vectors is the small transgene capacity ( approximately 4.6 kb). In this study, we constructed HSV/AAV hybrid vectors that contained, in addition to the standard HSV-1 amplicon elements, AAV rep68, rep78, both rep68 and -78, or all four rep genes and a reporter gene that was flanked by the AAV inverted terminal repeats (ITRs). Southern blots of Hirt DNA from cells transfected with the hybrid vectors and HSV-1 helper DNA demonstrated that both the AAV elements and the HSV-1 elements were functional in the context of the hybrid vector. All hybrid vectors could be packaged into HSV-1 virions, although those containing rep sequences had lower titers than vectors that did not. Site-specific integration at AAVS1 on human chromosome 19 was directly demonstrated by PCR and sequence analysis of ITR-AAVS1 junctions in hybrid vector-transduced 293 cells. Cell clones that stably expressed the transgene for at least 12 months could easily be isolated without chemical selection. In the majority of these clones, the transgene cassette was integrated at AAVS1, and no sequences outside the ITR cassette, rep in particular, were present as determined by PCR, ITR rescue/replication assays, and Southern analysis. Some of the clones contained random integrations of the transgene cassette alone or together with sequences outside the ITR cassette. These data indicate that the long-term transgene expression observed following transduction with HSV/AAV hybrid vectors is, at least in part, supported by chromosomal integration of the transgene cassette, both randomly and site specifically.     

DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer

Gene transfer has been used to correct inherited immunodeficiencies, but in several patients integration of therapeutic retroviral vectors activated proto-oncogenes and caused leukemia. Here, we describe improved methods for characterizing integration site populations from gene transfer studies using DNA bar coding and pyrosequencing. We characterized 160 232 integration site sequences in 28 tissue samples from eight mice, where Rag1 or Artemis deficiencies were corrected by introducing the missing gene with gamma-retroviral or lentiviral vectors. The integration sites were characterized for their genomic distributions, including proximity to proto-oncogenes. Several mice harbored abnormal lymphoproliferations following therapy—in these cases, comparison of the location and frequency of isolation of integration sites across multiple tissues helped clarify the contribution of specific proviruses to the adverse events. We also took advantage of the large number of pyrosequencing reads to show that recovery of integration sites can be highly biased by the use of restriction enzyme cleavage of genomic DNA, which is a limitation in all widely used methods, but describe improved approaches that take advantage of the power of pyrosequencing to overcome this problem. The methods described here should allow integration site populations from human gene therapy to be deeply characterized with spatial and temporal resolution.